Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever

被引:81
作者
Fink, Joshua [1 ]
Gu, Feng [1 ]
Vasudevan, Subhash G. [1 ]
机构
[1] Novartis Inst Trop Dis, Singapore, Singapore
关键词
D O I
10.1002/rmv.507
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Dengue infections are a major cause of morbidity and mortality in the tropical and sub-tropical regions of the world. There is no vaccine for dengue and also there are no anti-viral drugs to treat the infection. Some patients, typically those experiencing a secondary infection with a different dengue serotype, may progress from an acute febrile disease to the more severe forms of disease, dengue haermorrhagic fever and dengue shock syndrome. Here we discuss the significant inummopathological component to severe disease and how T cells, cytokines and cross-reactive antibody combine to contribute to the progression to dengue haemorrhagic fever. These events are thought to lead to vascular leakage, the signature event in dengue haemorrhagic fever, and are addressed in this review by incorporating the concept of heterologous T cell immunity. The need for effective measures against dengue and dengue-related illness is clear. We propose that drugs against dengue virus, or the symptoms of severe dengue disease, are a viable goal. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:263 / 275
页数:13
相关论文
共 140 条
[1]   Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology [J].
Aichele, P ;
BrduschaRiem, K ;
Oehen, S ;
Odermatt, B ;
Zinkernagel, RM ;
Hengartner, H ;
Pircher, H .
IMMUNITY, 1997, 6 (05) :519-529
[2]   Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection [J].
An, J ;
Zhou, DS ;
Zhang, JL ;
Morida, H ;
Wang, JL ;
Yasui, K .
IMMUNOLOGY LETTERS, 2004, 95 (02) :167-174
[3]  
Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
[4]  
Avirutnan P, 1998, J IMMUNOL, V161, P6338
[5]   Characterisation of lymphocyte response and cytokine patterns in patients with Dengue fever [J].
Azeredo, EL ;
Zagne, SMO ;
Santiago, MA ;
Gouvea, AS ;
Santana, AA ;
Neves-Souza, PCF ;
Nogueira, RMR ;
Miagostovich, MP ;
Kubelka, CF .
IMMUNOBIOLOGY, 2001, 204 (04) :494-507
[6]  
BEYNON HLC, 1993, CLIN EXP IMMUNOL, V91, P314
[7]   Live attenuated tetravalent dengue vaccine [J].
Bhamarapravati, N ;
Sutee, Y .
VACCINE, 2000, 18 :44-47
[8]   Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge [J].
Bosch, I ;
Xhaja, K ;
Estevez, L ;
Raines, G ;
Melichar, H ;
Warke, RV ;
Fournier, MV ;
Ennis, FA ;
Rothman, AL .
JOURNAL OF VIROLOGY, 2002, 76 (11) :5588-5597
[9]   WHY DENGUE HEMORRHAGIC-FEVER IN CUBA .1. INDIVIDUAL RISK-FACTORS FOR DENGUE HEMORRHAGIC-FEVER DENGUE SHOCK SYNDROME (DHF DSS) [J].
BRAVO, JR ;
GUZMAN, MG ;
KOURI, GP .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1987, 81 (05) :816-820
[10]   Immune mediated and inherited defences against flaviviruses [J].
Brinton, MA ;
Kurane, I ;
Mathew, A ;
Zeng, LL ;
Shi, PY ;
Rothman, A ;
Ennis, FA .
CLINICAL AND DIAGNOSTIC VIROLOGY, 1998, 10 (2-3) :129-139